| Summary: | Rui Wang, Jun Shen, Huanhuan Yan, Xitao Gao, Tianfu Dong, Peishun Wang, Jun Zhou Department of Surgery, The First People’s Hospital of Lianyungang, Lianyungang, Jiangsu, ChinaCorrespondence: Jun Zhou Email dckaikai@sina.comAbstract: Disulfiram (DSF), also known as “Antabuse”, has been widely used in clinical practice to treat alcoholism. In the past decades, both in vivo and in vitro experiments showed that DSF has strong anti-cancer activity, there were some clinical studies indicated the administration of this drug was associated with favorable survival in breast cancer. It is also evident that DSF has a radioprotective effect on normal cells and could be utilized during the course of radiation therapy. Moreover, increasing evidences demonstrated the role of DSF in enhancing the radiosensitivity of tumor cells in number of alternative mechanisms. Recent studies have also elaborated the anticancer mechanism of DSF in tumor cells. This review summarizes the anticancer activity of DSF both in preclinical studies and clinical trials, focuses on the advances of this drug in radiobiology and the treatment of breast cancer, and reveals the promising of repurposing DSF as a novel radiosensitizer and radioprotector in further clinical trials.Keywords: disulfiram, breast cancer, clinical studies, radiobiology, radiosensitivity
|
|---|
